Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsUnitedHealthcare Carbaglu Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentUnitedHealthcarePolicy N/A

    Carbaglu (carglumic acid) Coverage Criteria

    Customize your policy alerts

    Sign up for all UnitedHealthcare policy alerts

    Know when UnitedHealthcare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and reauthorization for Carbaglu in pediatric and adult patients with hyperammonemia associated with N-acetylglutamate synthase deficiency, propionic acidemia, or methylmalonic acidemia. Coverage requires an eligible diagnosis for initial authorization and documentation of positive clinical response for reauthorization.

    Policy Summary
    PayerUnitedHealthcare
    PolicyCarbaglu (carglumic acid) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOctober 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateNot specified
    Key ActionFor reauthorization, provide documentation demonstrating a positive clinical response to Carbaglu therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Covered hyperammonemia etiologies
    12 monthsInitial authorization duration
    12 monthsReauthorization duration
    No changeAnnual review impact

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Authorization Coverage Criteria

    Initial Authorization

    Covered for initial authorization when the diagnosis criterion is met.

    Eligible cause of hyperammonemia

    • N-acetylglutamate synthase deficiency: N-acetylglutamate synthase (NAGS) deficiency.
    • Propionic acidemia (PA).
    • Methylmalonic acidemia (MMA).

    Reauthorization

    Covered for reauthorization when the continuation criterion is met.

    Positive clinical response: Documentation of positive clinical response to Carbaglu therapy.

    Documentation and Authorization Requirements

    Prior Authorization

    Document an eligible diagnosis

    For initial authorization, document a diagnosis of hyperammonemia due to one of the following: N-acetylglutamate synthase (NAGS) deficiency, propionic acidemia (PA), or methylmalonic acidemia (MMA).

    • N-acetylglutamate synthase (NAGS) deficiency
    • Propionic acidemia (PA)
    • Methylmalonic acidemia (MMA)
    Note

    Plan for 12-month authorization periods

    When the applicable coverage criteria are met, authorization for Carbaglu is issued for 12 months for both initial authorization and reauthorization.

    • Initial authorization: 12 months
    • Reauthorization: 12 months

    Carbaglu Background

    Carbaglu (carglumic acid) is a carbamoyl phosphate synthetase 1 (CPS 1) activator. In pediatric and adult patients, it is used as maintenance therapy for chronic hyperammonemia caused by N-acetylglutamate synthase (NAGS) deficiency. Carbaglu is also used as adjunctive therapy to standard of care for acute hyperammonemia associated with NAGS deficiency, propionic acidemia, or methylmalonic acidemia.

    Initial Therapy Criteria

    Initial Authorization

    Initial authorization requires hyperammonemia due to one of the following conditions:

    Eligible cause of hyperammonemia

    • N-acetylglutamate synthase deficiency: N-acetylglutamate synthase (NAGS) deficiency.
    • Propionic acidemia (PA).
    • Methylmalonic acidemia (MMA).

    Continuation Therapy Criteria

    Reauthorization

    Reauthorization requires documentation of a positive clinical response to Carbaglu therapy.

    Positive clinical response: Documentation of positive clinical response to Carbaglu therapy.
    Policy Summary
    PayerUnitedHealthcare
    PolicyCarbaglu (carglumic acid) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOctober 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateNot specified
    Key ActionFor reauthorization, provide documentation demonstrating a positive clinical response to Carbaglu therapy.
    SourceLink
    On This Page
    Authorization Coverage CriteriaDocumentation and Authorization RequirementsCarbaglu BackgroundInitial Therapy CriteriaContinuation Therapy Criteria
    Documentation Required

    Document positive clinical response

    For reauthorization, provide documentation demonstrating a positive clinical response to Carbaglu therapy.